Nanoscope Therapeutics Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2023

Nanoscope Therapeutics Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2023

DALLAS, Oct. 30, 2023 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and Eyecelerator @ AAO 2023 taking place in San Francisco, California. Details for the presentations are as follows:

Eyecelerator @ AAO 2023
Session Title: Retina Showcase
Session Date: November 2, 2023
Session Time: 12:40 p.m. P.T.
Location: San Francisco Marriott Marquis, Nob Hill Room
Presenter: Samuel Barone, M.D., Chief Medical Officer

During his presentation, Dr. Barone will showcase our Multi-Characteristic Opsin platform and its potential to restore vision based on recent clinical data in patients with advanced retinal degenerative diseases.

American Academy of Ophthalmology (AAO) 2023 Annual Meeting
Title: MCO-010 optogenetic therapy for vision loss in Stargardt disease: Topline data from the Phase 2 STARLIGHT trial
Session Title: RET14 (Section XI: Late Breaking Developments, Part II)
Session Date: November 4, 2023
Session Time: 9:10 a.m. P.T. (In Person, Live Broadcast, On Demand)
Location:  Moscone Center, West Building – Rm. 3004
Presenter: Stephen H. Tsang, M.D., Ph.D.

During his presentation, Dr. Tsang will discuss end-of-study data from our Phase 2 STARLIGHT trial of MCO-010 therapy in patients with severe vision loss due to Stargardt disease.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

SOURCE Nanoscope Therapeutics

On October 30, 2023   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Dr. Mohanty obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.